Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06803654 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 578
- Enrollment target
NCT06803654 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 578 participants.
The verdict
NCT06803654, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 578 participants
- Enrollment target
Study Summary
To demonstrate the efficacy of BTOS-HA as non inferior to Lumify for treating ocular redness in a population of adult subjects.
Interventions
- DRUG BTOS-HA
- DRUG Lumify®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 578 participants |
| Start Date | 2025-05-22 |
| Est. Completion | 2025-06-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06803654
The ClinicalTrials.gov registry entry for NCT06803654 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 578 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BTOS-HA is the first listed.
NCT06803654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06803654 about?
NCT06803654 is a clinical study titled "A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness". To demonstrate the efficacy of BTOS-HA as non inferior to Lumify for treating ocular redness in a population of adult subjects.
What is the current status of trial NCT06803654?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 578 participants. The study started on 2025-05-22. Estimated completion is 2025-06-29.
What interventions are being tested in trial NCT06803654?
The interventions under investigation include: BTOS-HA (DRUG), Lumify® (DRUG).
Who is sponsoring clinical trial NCT06803654?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.